Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Malignant Melanoma

Free Subscription 05.01.2026 3 Am J Dermatopathol 1 BMC Cancer 3 J Am Acad Dermatol 1 J Clin Invest 1 J Immunol 1 J Immunother 1 Melanoma Res 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Dermatopathol

1. MURPHY K, Helm MF, Pameijer C, Miller J, et al
   Pruritic Papular Eruption in a Male Receiving TVEC for Metastatic Melanoma.
   Am J Dermatopathol. 2026;48:e5-e6.
   PubMed        
   
   
2. MURPHY K, Helm MF, Pameijer C, Miller J, et al
   Pruritic Papular Eruption in a Male Receiving TVEC for Metastatic Melanoma: Answer.
   Am J Dermatopathol. 2026;48:72.
   PubMed        
   
   
3. IZOL H, Kolak Gozukucuk G, Bagbudar S, Caskan P, et al
   Evaluation of Preferentially Expressed Antigen in Melanoma Expression and Epidemiologic Features in Dysplastic Nevi: A Comparative Analysis of Low- and High-Grade Lesions.
   Am J Dermatopathol. 2025 Dec 26. doi: 10.1097/DAD.0000000000003203.
   PubMed         Abstract available
   
   

   
   BMC Cancer

4. YUAN B, Huang K, Yang Q, Li M, et al
   The role of transcription factor TBX19 in melanoma: a comprehensive bioinformatics analysis and cellular experiments.
   BMC Cancer. 2025 Dec 28. doi: 10.1186/s12885-025-15473.
   PubMed        
   
   

   
   J Am Acad Dermatol

5. HADFIELD MJ, Muzumdar S, Sullivan RJ, Katz S, et al
   Updates in Adjuvant and Neoadjuvant Therapies for Resectable Cutaneous Melanoma.
   J Am Acad Dermatol. 2025 Dec 24:S0190-9622(25)03450.
   PubMed         Abstract available
   
   
6. LU Y, Liang Z, Ye S, Ye J, et al
   Variations in Characteristics and Clinical Outcomes of Cutaneous Melanoma Among Asian Americans: An Analysis of Surveillance, Epidemiology, and End Results Database.
   J Am Acad Dermatol. 2025 Dec 24:S0190-9622(25)03455.
   PubMed        
   
   
7. COSTELLO CM, Ho A, Kechter J, Nussbaum RL, et al
   Germline Cancer Susceptibility Gene Testing in Unselected Patients with Malignant Melanoma: A Multicenter Prospective Study.
   J Am Acad Dermatol. 2025 Dec 20:S0190-9622(25)03441.
   PubMed        
   
   

   
   J Clin Invest

8. NJAUW CN, Ji Z, Latoni DI, Villa-Gonzalez JM, et al
   Germline inactivation of tumor suppressor BAP1 is associated with white spotting.
   J Clin Invest. 2026;136:e195809.
   PubMed         Abstract available
   
   

   
   J Immunol

9. GIRARD M, Yu T, Batista NV, Yeung KKM, et al
   STING agonists drive recruitment and intrinsic type I interferon responses in monocytic lineage cells for optimal anti-tumor immunity.
   J Immunol. 2025;214:3634-3646.
   PubMed         Abstract available
   
   

   
   J Immunother

10. BOYER M, Kerimian M, Ribadeau Dumas A, Korbi S, et al
    Brief Communication: Severe Immuno-Induced Rhinosinusitis With Deafness After Ipilimumab and Nivolumab Combination for Melanoma, and Review of the Literature.
    J Immunother. 2025 Dec 23. doi: 10.1097/CJI.0000000000000592.
    PubMed         Abstract available
    
    

    
    Melanoma Res

11. MULLINS KR, Guo JJ
    Trends of adverse event reports associated with BRAF and MEK inhibitors and combinations: a retrospective disproportionality analysis using the FDA adverse event reporting system database from 2012 to 2021.
    Melanoma Res. 2026;36:58-63.
    PubMed         Abstract available
    
    

    
    PLoS One

12. MCLOUGHLIN KG, Watts CG, Wade S, Smit AK, et al
    A protocol for development of a microsimulation model platform to evaluate the potential benefits, harms, and cost-effectiveness of risk-tailored melanoma screening.
    PLoS One. 2025;20:e0339177.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.